A consortium of investors led a $300m Series C funding round in Tessera Therapeutics.

A consortium of investors led a $300m Series C funding round in Tessera Therapeutics, a biotechnology company, with participation from Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, SALT Fund, SoftBank Vision Fund 2 and T. Rowe Price. “We are thankful for the support from our new partners and existing investors alike in this latest funding round. It is our belief that genetic medicine will be the most important next epoch in medicine—offering the ability to cure genetic diseases and to someday even prevent disease from occurring. Today’s announcement will help us realize the promise of GENE WRITING technology and our mission of curing disease by writing in the code of life," Geoffrey von Maltzahn, Tessera Therapeutics Co-Founder, CEO and Board Director.